Mechanism of Action
Unimolecular GLP-1/Amylin Dual Agonism
Unlike a fixed-dose combination of two separate drugs (e.g. CagriSema), amycretin links a GLP-1 receptor agonist peptide and an amylin receptor agonist peptide covalently into a single molecule. This dual activation targets both the GLP-1-driven satiety pathway and the amylin-driven gastric-emptying/satiety pathway simultaneously, which Novo Nordisk's trial data suggests produces greater weight loss than either mechanism alone.
Research Summary
Subcutaneous Phase 1b/2a (NCT06049329)
Phase 1b/2a CompleteRandomized, placebo-controlled, single-center, double-blind trial, 125 adults with overweight/obesity, up to 36 weeks. Doses tested: 1.25 mg, 5 mg, 20 mg, and up to 60 mg once weekly. Highest doses produced 24.3% mean weight loss vs 1.1% with placebo. Published in The Lancet (2025).
Oral Phase 1
Phase 1 CompleteSingle-center, randomized, placebo-controlled trial, 144 adults with overweight/obesity, up to 12 weeks. Single and multiple ascending oral doses up to 2x50 mg (100 mg total) daily. 100 mg/day produced 13.1% mean weight loss vs 1.2% with placebo.
Type 2 Diabetes (NCT06542874)
Phase 2A separate Phase 2 trial in type 2 diabetes reported significant weight loss and HbA1c reduction, supporting advancement of the subcutaneous formulation to Phase 3.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Subcutaneous Phase 1b/2a reference | 1.25 mg, 5 mg, 20 mg, or up to 60 mg once weekly | Weekly | Subcutaneous |
| Oral Phase 1 reference | Up to 100 mg/day (2 x 50 mg) | Daily | Oral |
Not yet approved. These are published Phase 1/2 trial arm designs (NCT06049329), shown for research reference only, not a consumer protocol, vendor research-peptide recipe, or medical recommendation. No vendor has published a human-dosing vial size, so the calculator below defaults to a placeholder vial, enter your own vial size and water volume.
Interactions
Safety Profile
Both subcutaneous and oral formulations showed predominantly mild-to-moderate gastrointestinal effects, nausea, vomiting, and decreased appetite, occurring in a dose-dependent manner. No long-term human safety data exists yet; amycretin remains in Phase 3 trials.
References
- [1]Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10505):149-162.